Objective: The optimal treatment strategy for large-vessel occlusion (LVO) related to intracranial atherosclerotic disease (ICAD), particularly for tandem lesions that complicate access and device delivery, remains unclear. We report a case in which angioplasty with a stent retriever (SR) and combined antithrombotic therapy was effective in treating re-occlusion associated with dissection of the residual stenosis after thrombectomy for acute atherosclerotic occlusion of the basilar artery (BA) with the left vertebral artery (VA) stenosis.

Case Presentation: An 80-year-old woman was brought to our hospital with progressively worsening consciousness and tetra-paresis. MRA revealed occlusion of the middle to proximal portion of the BA. The patient underwent percutaneous transluminal angioplasty using a balloon catheter for severe stenosis at the origin of the left VA, followed by mechanical thrombectomy for the BA occlusion. While initial recanalization was achieved, residual stenosis in the proximal portion of the BA led to re-occlusion. An attempt at angioplasty with a balloon catheter failed to reach the stenotic segment due to stenosis and tortuosity of the left VA. Consequently, the SR was redeployed into the BA, and a loading dose of antiplatelet agents and intravenous anticoagulant were administered during prolonged deployment. Following the confirmation of BA patency, the SR was re-sheathed and removed. The patient achieved remarkable improvement in consciousness and tetra-paresis without postoperative re-occlusion of the BA.

Conclusion: Angioplasty with a SR and combined antithrombotic therapy may be a useful treatment option for ICAD-related LVO, particularly in cases such as tandem lesions that hinder access and make distal balloon catheter navigation challenging.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851022PMC
http://dx.doi.org/10.5797/jnet.cr.2024-0056DOI Listing

Publication Analysis

Top Keywords

combined antithrombotic
12
antithrombotic therapy
12
balloon catheter
12
acute atherosclerotic
8
basilar artery
8
angioplasty stent
8
stent retriever
8
retriever combined
8
tandem lesions
8
residual stenosis
8

Similar Publications

Thrombotic response to mechanical circulatory support devices.

J Thromb Haemost

March 2025

School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Charles Perkins Centre, The University of Sydney, NSW 2006, Australia; The University of Sydney Nano Institute, The University of Sydney, NSW 2006, Australia. Electronic address:

Cardiovascular mechanical circulatory support (MCS) device use triggers thrombosis and haemostatic disorders, which may become fatal if thrombi occlude circulation or cause embolic complications. Consequently, anti-thrombotic medications are administered, which often cannot eliminate thrombosis, and further compromise patient survival by introducing an additional risk of severe bleeding events. MCS thrombosis is induced and affected by the combined relationships of patient pathology, the foreign artificial biomaterial's surface properties, and pathological flow conditions.

View Article and Find Full Text PDF

Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer.

View Article and Find Full Text PDF

Triple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection.

View Article and Find Full Text PDF

Introduction: The high prevalence of patients with embolic stroke of undetermined source (ESUS), the considerable risk of ischemic stroke, and the need for novel antithrombotic strategies highlight ESUS as an important priority in stroke research in the coming years. This study is designed to investigate the effectiveness and safety of rivaroxaban along with aspirin in reducing stroke recurrence in patients with ESUS.

Materials And Methods: The present study is a parallel-group, placebo-controlled, randomized, outcome-assessor blind, on patients in whom ESUS has recently (7-60 days) identified and had one risk factor of a potential embolic source.

View Article and Find Full Text PDF

Research progress of cervicocerebral artery dissection, from mechanism to clinic: A scoping review.

Am J Emerg Med

February 2025

Neurology, Nanhai Hospital of Traditional Chinese Medicine, Jinan University, Foshan 528200, China. Electronic address:

Cervicocerebral artery dissection (CAD) commonly occurs in young individuals, and its clinical manifestations lack specificity. It can present as either ischemic or hemorrhagic events. Due to variations in the location, timing of formation, and severity of the lesion in CAD, clinical presentations vary widely, making imaging crucial for accurate diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!